KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Equity Income (2016 - 2019)

CRISPR Therapeutics AG's Equity Income history spans 4 years, with the latest figure at -$3.4 million for Q3 2019.

  • For Q3 2019, Equity Income fell 238.93% year-over-year to -$3.4 million; the TTM value through Dec 2019 reached -$5.5 million, down 27.88%, while the annual FY2019 figure was -$5.5 million, 27.88% down from the prior year.
  • Equity Income for Q3 2019 was -$3.4 million at CRISPR Therapeutics AG, down from -$1.0 million in the prior quarter.
  • Across five years, Equity Income topped out at -$359000.0 in Q3 2017 and bottomed at -$35.8 million in Q4 2016.
  • The 4-year median for Equity Income is -$1.0 million (2018), against an average of -$3.9 million.
  • The largest annual shift saw Equity Income soared 98.74% in 2017 before it crashed 238.93% in 2019.
  • A 4-year view of Equity Income shows it stood at -$35.8 million in 2016, then skyrocketed by 98.74% to -$453000.0 in 2017, then tumbled by 124.94% to -$1.0 million in 2018, then tumbled by 236.6% to -$3.4 million in 2019.
  • Per Business Quant, the three most recent readings for CRSP's Equity Income are -$3.4 million (Q3 2019), -$1.0 million (Q2 2019), and -$1.0 million (Q1 2019).